Navigation Links
Invibio Biomaterial Solutions Announces Global Launch of “PEEK-OPTIMA HA Enhanced Polymer”
Date:9/9/2013

West Conshohocken, Philadelphia, PA (PRWEB) September 09, 2013

Invibio Biomaterial Solutions, the leading solutions provider of PEEK-based biomaterials, manufacturing and application knowledge to medical device manufacturers worldwide, has today announced its launch of “PEEK-OPTIMA HA Enhanced Polymer”. The implantable biomaterial grade uniquely combines two clinically proven advanced biomaterials for enhanced bone apposition (1): PEEK-OPTIMA, the principal PEEK-based biomaterial with over ten years of proven history in clinical use, and Hydroxyapatite (HA), a well-known osteoconductive material.

Hydroxyapatite (HA) is fully integrated into the PEEK-OPTIMA Natural grade to provide a complete homogeneous compound which ensures that HA will be present at all surfaces of a device. John Devine, Emerging Business Director explained, “Although PEEK is the most popular chosen material for interbody fusion applications, surgeon feedback has indicated that a version of PEEK that enhances bone ongrowth on all sides of the device could be more effective. Invibio has invested in this new grade that offers the same advantages of PEEK-OPTIMA® and additionally a superior solution for bone apposition. With HA available across the whole device the opportunity for bone ongrowth is virtually unmatched with alternative bone apposition technologies.” Devine concludes, “We believe the launch of PEEK-OPTIMA® HA Enhanced provides surgeons with improved technologies and enables device companies to differentiate their product offerings."

Early Bone Apposition

Within four weeks of implantation Invibio PEEK-OPTIMA HA Enhanced polymer demonstrated enhanced bone apposition compared to PEEK-OPTIMA® Natural, in a pre-clinical in vivo study using a sheep model. Within 12 weeks of implantation the bone apposition levels are maintained with the new grade.

PEEK-OPTIMA HA Enhanced Biomaterial provides excellent mechanical properties and performance, proven biocompatibility, a modulus similar to cortical bone, reducing stress shielding and a high degree of radiolucency that allows for clear fusion assessment. Developed by the world leader in implantable PEEK-based biomaterials this innovation not only offers the same processing simplicity as PEEK-OPTIMA, but also omits the extra processing time and expense of alternative bone on-growth technologies, such as coatings.

Professor Bill Walsh Director of Surgical & Orthopaedic Research Laboratories, University of New South Wales will present the latest data on PEEK-OPTIMA® HA Enhanced, the new material for bone apposition, at the upcoming spinal meetings Eurospine, 1-4 October 2013, Liverpool, UK and NASS, 9 – 11 October 2013, New Orleans USA. For more information visit: http://TurbochargeFUSION.com.

1 Study evaluated the bone in-growth and on-growth of PEEK-OPTIMA Natural and PEEK-OPTIMA HA Enhanced in a bone defect model in a sheep. Data on file at Invibio. This has not been correlated with human clinical experience.

About Invibio
Invibio® is a global leader providing high performance biomaterials, advanced technical research and consultative solutions to medical device manufacturers across a wide range of markets. The company provides medical device manufacturers with PEEK-OPTIMA® polymer and compounds, MOTIS® polymer, ENDOLIGN® composite and PEEK-CLASSIX® polymer for the development of long- and short-term implantable medical devices.

Media inquiries

Please contact Melanie Embery on +44 (0) 1253 898000 or membery(at)invibio(dot)com for all media enquiries. Alternatively, for more information visit http://www.invibio.com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11099082.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Regulatory Milestones for Invibio Biomaterial Solutions
2. ETEX Corporation to present at the 9th World Biomaterial Congress
3. Biomaterials China News 1210 - Annual Subscription
4. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
5. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
6. LA Dental Bone Graft Substitute & Other Biomaterials Market Reviewed in New iData Research Report Available at MarketPublishers.com
7. Blue Marble Biomaterials Secures Distribution Agreement with SAFC
8. Biomaterials Market worth $88.4 Billion - 2017
9. Global Biomaterial Market: To Grow at a 15% CAGR Says New Research Report at ReportsnReports.com
10. New Information Released on Measuring Zeta Potential and Surface Charge on Biomaterials
11. Global Biomaterials Market 2012-2016: Worldwide Industry Latest Market Share, Strategy, Growth, Size, Trends and Forecast Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):